HR. 1051In Committee
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Plain-English overview
What this bill does
Allows FDA approval of certain later-filed generic drug applications when a first filer does not begin commercial marketing within the required timeframe
Key points
- Require marketing within 75 days
- Authorize subsequent generic approvals
- Revoke eligibility
Current status
Where it stands
Status
In Committee
Latest action
2025-02-06 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.